Meiji Yasuda Asset Management Co Ltd. Acquires New Holdings in Boston Scientific Corporation $BSX

Meiji Yasuda Asset Management Co Ltd. bought a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,154 shares of the medical equipment provider’s stock, valued at approximately $433,000.

Other large investors have also recently added to or reduced their stakes in the company. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter worth $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the 1st quarter worth $28,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BSX shares. BTIG Research decreased their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, July 29th. Jefferies Financial Group dropped their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Truist Financial lowered their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Oppenheimer dropped their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity

In other news, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 1.7%

BSX stock opened at $49.86 on Wednesday. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $72.26 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. The business’s 50-day simple moving average is $46.44 and its 200 day simple moving average is $57.14.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has authorized a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.